Papua New Guinea

Papua New Guinea

Hepatitis B

Download HBV data

Prevalence of chronic HBV (HBsAg+)

National
Download
Value (%) Year Type Source
6.2 (5.82 - 6.47) 2019 Modelled IHME
6.34 (5.98 - 6.62) 2018 Modelled IHME
6.45 (6.01 - 6.77) 2017 Modelled IHME
6.51 (5.98 - 6.85) 2016 Modelled IHME
6.58 (5.80 - 6.96) 2015 Modelled IHME
6.68 (5.87 - 7.07) 2014 Modelled IHME
6.82 (6.04 - 7.21) 2013 Modelled IHME
6.98 (6.24 - 7.37) 2012 Modelled IHME
7.15 (6.41 - 7.54) 2011 Modelled IHME
7.3 (6.55 - 7.72) 2010 Modelled IHME
7.46 (6.72 - 7.87) 2009 Modelled IHME
7.61 (6.84 - 8.04) 2008 Modelled IHME
7.77 (6.93 - 8.23) 2007 Modelled IHME
7.92 (7.04 - 8.41) 2006 Modelled IHME
8.06 (7.15 - 8.59) 2005 Modelled IHME
8.19 (7.19 - 8.73) 2004 Modelled IHME
8.31 (7.24 - 8.88) 2003 Modelled IHME
8.43 (7.31 - 9.02) 2002 Modelled IHME
8.55 (7.35 - 9.16) 2001 Modelled IHME
8.68 (7.40 - 9.34) 2000 Modelled IHME
8.81 (7.51 - 9.51) 1999 Modelled IHME
8.95 (7.57 - 9.69) 1998 Modelled IHME
9.09 (7.67 - 9.89) 1997 Modelled IHME
9.23 (7.77 - 10.10) 1996 Modelled IHME
9.36 (7.88 - 10.30) 1995 Modelled IHME
9.49 (7.96 - 10.43) 1994 Modelled IHME
9.63 (8.07 - 10.53) 1993 Modelled IHME
9.76 (8.20 - 10.64) 1992 Modelled IHME
9.9 (8.34 - 10.77) 1991 Modelled IHME
10.03 (8.40 - 10.92) 1990 Modelled IHME
5.4 (4.34 - 6.79) 2015 Modelled WHO
Showing out of
Show more
Children under-5 years
Download
Value (%) Year Type Source
2.57 (1.89 - 3.15) 2019 Modelled IHME
2.64 (1.91 - 3.20) 2018 Modelled IHME
2.66 (1.88 - 3.28) 2017 Modelled IHME
2.5 (1.63 - 3.09) 2016 Modelled IHME
2.33 (1.35 - 2.98) 2015 Modelled IHME
2.31 (1.35 - 2.95) 2014 Modelled IHME
2.3 (1.36 - 2.93) 2013 Modelled IHME
2.29 (1.38 - 2.91) 2012 Modelled IHME
2.29 (1.38 - 2.89) 2011 Modelled IHME
2.29 (1.40 - 2.90) 2010 Modelled IHME
2.28 (1.41 - 2.89) 2009 Modelled IHME
2.27 (1.43 - 2.89) 2008 Modelled IHME
2.27 (1.46 - 2.91) 2007 Modelled IHME
2.26 (1.47 - 2.93) 2006 Modelled IHME
2.27 (1.49 - 2.94) 2005 Modelled IHME
2.33 (1.57 - 3.05) 2004 Modelled IHME
2.48 (1.67 - 3.21) 2003 Modelled IHME
2.7 (1.81 - 3.44) 2002 Modelled IHME
2.95 (1.97 - 3.69) 2001 Modelled IHME
3.2 (2.12 - 4.02) 2000 Modelled IHME
3.49 (2.30 - 4.39) 1999 Modelled IHME
3.85 (2.53 - 4.86) 1998 Modelled IHME
4.23 (2.77 - 5.40) 1997 Modelled IHME
4.58 (3 - 5.87) 1996 Modelled IHME
4.87 (3.22 - 6.30) 1995 Modelled IHME
5.1 (3.40 - 6.51) 1994 Modelled IHME
5.31 (3.54 - 6.72) 1993 Modelled IHME
5.5 (3.71 - 6.92) 1992 Modelled IHME
5.67 (3.79 - 7.06) 1991 Modelled IHME
5.8 (3.86 - 7.22) 1990 Modelled IHME
2.24 (1.68 - 2.85) 2015 Modelled WHO
2.3 2013 Survey/reported WHO WPRO, Woodring J et al, 2017
Showing out of
Show more

Percent of liver cancer deaths attributable to HBV

National
Download
Value (%) Year Type Source
48 (39 - 59) 2019 Modelled IHME
48 (39 - 59) 2018 Modelled IHME
48 (39 - 59) 2017 Modelled IHME
48 (39 - 58) 2016 Modelled IHME
48 (39 - 58) 2015 Modelled IHME
48 (39 - 58) 2014 Modelled IHME
48 (38 - 58) 2013 Modelled IHME
48 (39 - 58) 2012 Modelled IHME
48 (38 - 58) 2011 Modelled IHME
48 (38 - 58) 2010 Modelled IHME
48 (39 - 58) 2009 Modelled IHME
48 (39 - 58) 2008 Modelled IHME
48 (39 - 58) 2007 Modelled IHME
48 (39 - 58) 2006 Modelled IHME
48 (39 - 58) 2005 Modelled IHME
48 (39 - 58) 2004 Modelled IHME
48 (39 - 58) 2003 Modelled IHME
48 (38 - 57) 2002 Modelled IHME
48 (38 - 57) 2001 Modelled IHME
48 (38 - 57) 2000 Modelled IHME
48 (38 - 57) 1999 Modelled IHME
48 (38 - 57) 1998 Modelled IHME
48 (39 - 58) 1997 Modelled IHME
48 (38 - 58) 1996 Modelled IHME
48 (39 - 58) 1995 Modelled IHME
49 (39 - 59) 1994 Modelled IHME
49 (39 - 59) 1993 Modelled IHME
49 (40 - 59) 1992 Modelled IHME
49 (40 - 59) 1991 Modelled IHME
50 (40 - 60) 1990 Modelled IHME
Showing out of
Show more
Technical notes

Coverage of HepB birth dose

Newborns
Download
Value (%) Year Type Source
25 2018 Survey/reported WHO/UNICEF
33 2017 Survey/reported WHO/UNICEF
35 2016 Survey/reported WHO/UNICEF
32 2015 Survey/reported WHO/UNICEF
31 2014 Survey/reported WHO/UNICEF
37 2013 Survey/reported WHO/UNICEF
35 2012 Survey/reported WHO/UNICEF
31 2011 Survey/reported WHO/UNICEF
31 2010 Survey/reported WHO/UNICEF
26 2009 Survey/reported WHO/UNICEF
27 2008 Survey/reported WHO/UNICEF
29 2007 Survey/reported WHO/UNICEF
35 2006 Survey/reported WHO/UNICEF
Showing out of
Show more
Technical notes

Coverage of 3-dose hepatitis B vaccine

Infants
Download
Value (%) Year Type Source
61 2018 Survey/reported WHO/UNICEF
62 2017 Survey/reported WHO/UNICEF
72 2016 Survey/reported WHO/UNICEF
73 2015 Survey/reported WHO/UNICEF
73 2014 Survey/reported WHO/UNICEF
79 2013 Survey/reported WHO/UNICEF
74 2012 Survey/reported WHO/UNICEF
72 2011 Survey/reported WHO/UNICEF
67 2010 Survey/reported WHO/UNICEF
66 2009 Survey/reported WHO/UNICEF
59 2008 Survey/reported WHO/UNICEF
61 2007 Survey/reported WHO/UNICEF
71 2006 Survey/reported WHO/UNICEF
63 2005 Survey/reported WHO/UNICEF
60 2004 Survey/reported WHO/UNICEF
67 2003 Survey/reported WHO/UNICEF
60 2002 Survey/reported WHO/UNICEF
59 2001 Survey/reported WHO/UNICEF
57 2000 Survey/reported WHO/UNICEF
54 1999 Survey/reported WHO/UNICEF
47 1998 Survey/reported WHO/UNICEF
44 1997 Survey/reported WHO/UNICEF
43 1996 Survey/reported WHO/UNICEF
23 1995 Survey/reported WHO/UNICEF
20 1994 Survey/reported WHO/UNICEF
7 1993 Survey/reported WHO/UNICEF
12 1992 Survey/reported WHO/UNICEF
19 1991 Survey/reported WHO/UNICEF
20 1990 Survey/reported WHO/UNICEF
Showing out of
Show more

Number of needles/syringes per PWID per year

People who inject drugs (PWID)
Download
Value Year Type Source
0 (0 - 0) 2016 Survey/reported Harm Reduction International, 2016

Percent of PWID accessing OST

People who inject drugs (PWID)
Download
Value (%) Year Type Source
0 2016 Survey/reported Harm Reduction International, 2016
HBV National Action Plan
HBV elimination goal
HepB birth dose policy
Yes
Year of birth dose introduction
1998
Eligible for HBV generic medicines
HCV National Action Plan
HCV elimination goal
Eligible for HCV generic medicines
At least one needle-syringe exchange program (NSP) operational
No
At least one opioid substitution therapy (OST) program operational
No
NSP in at least one prison
No
OST in at least one prison
No
% of substance use disorder facilities offering hepatitis testing
None
% of substance use disorder facilities offering hepatitis treatment
None

Hepatitis C

Download HCV data

Prevalence of chronic HCV (RNA+/cAg)

National
Download
Value (%) Year Type Source
1.01 (0.81 - 1.26) 2019 Modelled IHME
1.01 (0.80 - 1.26) 2018 Modelled IHME
1.01 (0.80 - 1.28) 2017 Modelled IHME
1.01 (0.81 - 1.26) 2016 Modelled IHME
1.01 (0.81 - 1.24) 2015 Modelled IHME
1.01 (0.81 - 1.25) 2014 Modelled IHME
1.02 (0.82 - 1.27) 2013 Modelled IHME
1.04 (0.83 - 1.29) 2012 Modelled IHME
1.06 (0.83 - 1.32) 2011 Modelled IHME
1.07 (0.84 - 1.35) 2010 Modelled IHME
1.09 (0.86 - 1.36) 2009 Modelled IHME
1.11 (0.89 - 1.38) 2008 Modelled IHME
1.14 (0.92 - 1.40) 2007 Modelled IHME
1.17 (0.94 - 1.43) 2006 Modelled IHME
1.2 (0.97 - 1.47) 2005 Modelled IHME
1.25 (1.01 - 1.52) 2004 Modelled IHME
1.3 (1.06 - 1.58) 2003 Modelled IHME
1.36 (1.11 - 1.66) 2002 Modelled IHME
1.42 (1.16 - 1.74) 2001 Modelled IHME
1.46 (1.19 - 1.81) 2000 Modelled IHME
1.5 (1.22 - 1.84) 1999 Modelled IHME
1.53 (1.25 - 1.87) 1998 Modelled IHME
1.56 (1.26 - 1.91) 1997 Modelled IHME
1.58 (1.26 - 1.94) 1996 Modelled IHME
1.59 (1.27 - 1.96) 1995 Modelled IHME
1.58 (1.26 - 1.93) 1994 Modelled IHME
1.54 (1.23 - 1.89) 1993 Modelled IHME
1.48 (1.18 - 1.82) 1992 Modelled IHME
1.4 (1.11 - 1.73) 1991 Modelled IHME
1.31 (1.03 - 1.63) 1990 Modelled IHME
Showing out of
Show more

Percent of liver cancer deaths attributable to HCV

National
Download
Value (%) Year Type Source
24 (16 - 32) 2019 Modelled IHME
24 (16 - 32) 2018 Modelled IHME
25 (16 - 32) 2017 Modelled IHME
25 (17 - 32) 2016 Modelled IHME
25 (17 - 33) 2015 Modelled IHME
25 (17 - 33) 2014 Modelled IHME
25 (17 - 33) 2013 Modelled IHME
25 (17 - 33) 2012 Modelled IHME
25 (17 - 33) 2011 Modelled IHME
25 (17 - 33) 2010 Modelled IHME
25 (17 - 33) 2009 Modelled IHME
25 (17 - 33) 2008 Modelled IHME
25 (17 - 34) 2007 Modelled IHME
26 (17 - 34) 2006 Modelled IHME
26 (18 - 34) 2005 Modelled IHME
26 (18 - 34) 2004 Modelled IHME
26 (18 - 34) 2003 Modelled IHME
26 (18 - 34) 2002 Modelled IHME
26 (18 - 35) 2001 Modelled IHME
26 (18 - 34) 2000 Modelled IHME
26 (18 - 34) 1999 Modelled IHME
26 (18 - 35) 1998 Modelled IHME
26 (18 - 35) 1997 Modelled IHME
26 (18 - 35) 1996 Modelled IHME
26 (18 - 35) 1995 Modelled IHME
26 (17 - 34) 1994 Modelled IHME
25 (17 - 34) 1993 Modelled IHME
25 (17 - 34) 1992 Modelled IHME
25 (17 - 33) 1991 Modelled IHME
25 (17 - 33) 1990 Modelled IHME
Showing out of
Show more
Technical notes

Number of needles/syringes per PWID per year

People who inject drugs (PWID)
Download
Value Year Type Source
300 (0 - 0) 2016 Survey/reported Harm Reduction International, 2016

Percent of PWID accessing OST

People who inject drugs (PWID)
Download
Value (%) Year Type Source
0 2016 Survey/reported Harm Reduction International, 2016
HBV National Action Plan
HBV elimination goal
HepB birth dose policy
Yes
Year of birth dose introduction
1998
Eligible for HBV generic medicines
HCV National Action Plan
HCV elimination goal
Eligible for HCV generic medicines
At least one needle-syringe exchange program (NSP) operational
No
At least one opioid substitution therapy (OST) program operational
No
NSP in at least one prison
No
OST in at least one prison
No
% of substance use disorder facilities offering hepatitis testing
None
% of substance use disorder facilities offering hepatitis treatment
None

Overview

HBV elimination goal
HCV elimination goal

Prevalence (national)

Modelled

HBV (HBsAg+)
6.2 (%)
2019
(5.82 - 6.47(%))
IHME
HCV (RNA/cAg+)
1.01 (%)
2019
(0.81 - 1.26(%))
IHME

Survey/surveillance

No data available
No data available

Hepatitis related deaths (national)

Modelled

HBV
289
2019
(200 - 410)
IHME

Survey/surveillance

No data available
HBV chart

Modelled

HCV
191
2019
(125 - 275)
IHME

Survey/surveillance

No data available
HCV chart

Prevalence < 5

HBV
2.30 (%)
2013, survey/surveillance
WHO WPRO, Woodring J et al, 2017

Prevalence PWID

No data available

Birth dose vaccination coverage (national)

Survey/surveillance

HBV
25 (%)
2018
WHO/UNICEF

No. of syringes/PWID/year

Survey/surveillance

HCV
0
2016
(0 - 0)
Harm Reduction International, 2016
Eligible for HBV generic medicines
Eligible for HCV generic medicines